Biopharmaceutical
Pharmaceutical
Health

Esperion Therapeutics

$44.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.31 (0.71%) Pre-Market
+$0.31 (0.71%) Pre-Market

Why Robinhood?

You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!

About

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Employees
76
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
1.18B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
824.96K
High Today
$48.17
Low Today
$43.87
Open Price
$48.17
Volume
674.80K
52 Week High
$79.30
52 Week Low
$33.06

Collections

Biopharmaceutical
Pharmaceutical
Health
Top Movers
Research And Development
Therapy
Biotechnology
Medical

News

Guru FocusMar 14

Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares

President & CEO of Esperion Therapeutics Inc (NASDAQ:ESPR) Timothy M Mayleben bought 5,000 shares of ESPR on 03/14/2019 at an average price of $48.73 a share.

181
Markets InsiderMar 14

Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced Marker of Underlying Cardiovascular Inflammation, with...

Bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) Inhibitor that reduces cholesterol and fatty acid synthesis in the liver Study 1 is the largest of a comprehensive five Phase 3 study programme investigating the benefits of bempedoic acid in patients requiring additional low-density lipoprotein cholesterol (LDL-C) lowering Over 52-weeks, bempedoic acid was observed to be well-tolerated, and did not lead to higher overall adverse events compared with placebo Treated patients showed lower rates...

110
Markets InsiderMar 13

Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine

– Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – – Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – Research by Professor Kausik Ray, published in the March 14th, 2019 New England Journal of Medicine – ANN ARBOR, Mich., Marc...

72

Earnings

-$2.24
-$1.97
-$1.69
-$1.42
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.